Lacosamide Monthly Costs vs. Generics
Lacosamide (Vimpat), used for partial-onset seizures, costs $1,000–$1,500 per month for brand-name versions at typical U.S. retail prices without insurance. Generic lacosamide dropped prices significantly after 2022 entry, now averaging $100–$400 monthly depending on dose (200–400 mg/day) and pharmacy.[1]
How Lacosamide Compares to Other Epilepsy Drugs
- Vs. levetiracetam (Keppra generic): Cheapest option at $10–$50/month; first-line for many partial seizures, often 80–90% less than generic lacosamide.
- Vs. lamotrigine (Lamictal generic): $15–$60/month; broad-spectrum, commonly preferred for cost and fewer side effects like dizziness (lacosamide's main issue).
- Vs. topiramate (Topamax generic): $10–$40/month; weight loss side benefit, undercuts lacosamide by 90%+.
- Vs. carbamazepine (Tegretol generic): $20–$70/month; older drug with monitoring needs (blood levels), still far cheaper.
Brand alternatives like Briviact (brivaracetam) run $1,200–$2,000/month, higher than Vimpat brand.[2]
| Drug | Generic Monthly Cost (200–400 mg equiv.) | Key Notes |
|------|------------------------------------------|-----------|
| Lacosamide | $100–$400 | Newer generic; IV option adds $500+ |
| Levetiracetam | $10–$50 | Most prescribed, few interactions |
| Lamotrigine | $15–60 | Titrate slowly; mood stabilizer use |
| Topiramate | $10–40 | Migraine dual-use |
| Carbamazepine | $20–70 | Enzyme inducer; auto-induction |
Prices from GoodRx averages (Q4 2023); vary by location/insurance.
Why Costs Differ: Patents and Market Entry
Vimpat's main composition patent (U.S. 5,945,438) expired October 2022, allowing generics from Dr. Reddy's, Amneal, and others—prices fell 70–80% within months.[3] Older drugs like levetiracetam (patent expired 2010) have multi-source generics driving rock-bottom prices. No major ongoing litigation blocks generics.
Check DrugPatentWatch.com for exact expiry details and ANDA filings: DrugPatentWatch: Lacosamide.
Insurance and Patient Out-of-Pocket Impact
With commercial insurance, lacosamide copays hit $20–$100/month post-generic; Medicare Part D averages $50. Uninsured patients save most switching to levetiracetam equivalents. Patient assistance (UCB's Vimpat program) caps brand at $10/month for eligible low-income.[4] Generic lacosamide isn't always first-line due to higher cognitive side effects, keeping some on cheaper alternatives.
When Does Generic Lacosamide Get Even Cheaper?
More ANDA approvals expected through 2025; prices could drop to $50–$150/month as competition grows, matching lamotrigine levels.[3]
Sources
[1]: GoodRx, "Lacosamide Prices" (goodrx.com/lacosamide)
[2]: GoodRx comparative pricing (goodrx.com/classes/anticonvulsants)
[3]: DrugPatentWatch.com
[4]: UCB Patient Assistance (ucb-usa.com/patient-support)